Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Notes Payables (2025)

Iovance Biotherapeutics has reported Notes Payables over the past 3 years, most recently at $1.0 million for Q4 2025.

  • Quarterly results put Notes Payables at $1.0 million for Q4 2025, changed N/A from a year ago — trailing twelve months through Dec 2025 was $1.0 million (changed N/A YoY), and the annual figure for FY2025 was $1.0 million, changed.
  • Notes Payables for Q4 2025 was $1.0 million at Iovance Biotherapeutics, roughly flat from $1.0 million in the prior quarter.
  • Over the last five years, Notes Payables for IOVA hit a ceiling of $1.0 million in Q1 2025 and a floor of $1.0 million in Q1 2025.